Morgan Stanley Upgrades Boston Scientific on Pipeline Acceleration

In a report published Monday, Morgan Stanley analyst David Lewis upgraded Boston Scientific Corporation BSX from Equal-weight to Overweight based on pipeline acceleration traction. Despite disappointing pipeline progress in 2013 from Asthmatx reimbursement delays and S-ICD manufacturing constraints, Morgan Stanley expects sales results to improve. Morgan Stanley's updated model shows risk-adjusted pipeline sales of $90 million (130 bps) in 2014 and $145 million (180 bps) in 2015, which drives a $0.07 (8%) EPS accretion by 2015. Lewis reported that Boston Scientific has the best opportunity for margin improvements in cardiology. The analyst commented, “At 19%, cash operating margins are depressed relative to peers. In particular, CRM margins of 12-13% are half those of competitors; normalizing CRM profitability alone could drive 15%+ upside to EPS over several years. Structural cost programs have done an impressive job of supporting the P&L during a multi-year contraction in revenue, but margin results should accelerate in a more visible way as revenue growth rates push into the mid single digits and drive much better leverage over a fully-loaded expense structure.” Shares of Boston Scientific Corporation closed at $11.93 on Friday and is currently trading at $12.28, up 2.93%.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsDavid LewisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!